Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Zhao, Leia; 1 | Liu, Lijuanb; 1 | Zhao, Haiyanc | Bao, Jiaqid | Dou, Yanae | Yang, Zhenxinga | Lin, Yange | Sun, Zhentinga | Meng, Lingxina | Yan, Lif | Liu, Aishia; *
Affiliations: [a] Department of Radiology, the Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China | [b] Department of Radiology, the Affiliated Beijing Chuiyangliu Hospital of Tsinghua University, Beijing, China | [c] Department of Oncology, the Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China | [d] Department of Oncology, Inner Mongolia People’s Hospital, Inner Mongolia, China | [e] Department of Scientific Marketing, Siemens Healthineers AG, China | [f] Department of Respiratory, the Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China
Correspondence: [*] Corresponding author: Aishi Liu, PhD, MD, Department of Radiology, the Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao North Street, Hohhot, Inner Mongolia 010050, China. Tel.: +86 0471 3451643; E-mail: [email protected].
Note: [1] These authors contributed equally to this work as co-first authors.
Abstract: OBJECTIVE:To investigate feasibility of the quantitative parameters of dual-energy computed tomography (DECT) to assess therapy response in advanced non-small cell lung cancer (NSCLC) compared with the traditional enhanced CT parameters based on the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. METHODS:Forty-five patients with unresectable locally advanced NSCLC who underwent DECT before and after chemotherapy or concurrent chemoradiotherapy (cCRT) were prospectively enrolled. By comparing baseline studies with follow-up, patients were divided into two groups according to RECIST guidelines as follows: disease control (DC, including partial response and stable disease) and progressive disease (PD). The diameter (D), attenuation, iodine concentration and normalized iodine concentration of arterial and venous phases (ICA, ICv, NICA, NICv) and the percentage of these changes pre- and post-therapy were measured and calculated. The Pearson correlation was used to analyze correlation between various quantitative parameters. The receiver operating characteristic (ROC) curves were used to evaluate accuracy of therapy response prediction. RESULTS:The change percentages of Attenuation (Δ-Attenuation-A and Δ-Attenuation-V), IC (ΔICA and ΔICV) and NIC (ΔNICA and ΔNICV) pre- and post-therapy correlate with the change percentage of D (ΔD). Among these, ΔICA strongly correlates with ΔD (r = 0.793, P < 0.001). The areas under ROC curves generated using Δ-Attenuation-A, ΔICA, and ΔNICA are 0.796, 0.900, and 0.880 with the corresponding cutoff value of 9.096, −15.692, and −4.7569, respectively, which are significantly different (P < 0.001). CONCLUSIONS:The quantitative parameters of DECT iodine map, especially iodine concentration, in arterial phase provides a new quantitative image marker to predict therapy response of patients diagnosed with advanced NSCLC.
Keywords: Dual-energy CT, therapeutic response, non-small cell lung cancer (NSCLC), quantitative image marker
DOI: 10.3233/XST-210989
Journal: Journal of X-Ray Science and Technology, vol. 30, no. 1, pp. 111-122, 2022
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]